P/E at 37.18 vs Industry's 34.85: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflecting Market Confidence

Sun Pharmaceutical Industries Ltd currently trades at a P/E of 37.18, which is approximately 6.7% higher than the Pharmaceuticals & Biotechnology industry average of 34.85. This premium suggests that investors are willing to pay more for the stock relative to its peers, potentially reflecting expectations of superior earnings growth or stability. However, this valuation is not excessively stretched compared to some high-growth peers in the sector. The premium is consistent with the company’s large-cap status and its track record of delivering steady returns over the years. Previously rated Strong Buy, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: A Tale of Contrasting Momentum

Examining the stock’s returns reveals a strong outperformance relative to the Sensex across multiple periods. Over the past year, Sun Pharmaceutical Industries Ltd has gained 9.81%, while the Sensex declined by 7.99%. This positive alpha extends to shorter timeframes as well, with the stock up 3.15% over the last week compared to a marginal 0.12% rise in the Sensex. The one-month and three-month returns are particularly notable, at 12.82% and 9.13% respectively, contrasting sharply with the Sensex’s declines of 4.87% and 9.80% over the same periods. Year-to-date, the stock has appreciated 9.43%, while the Sensex has fallen 12.35%. This consistent outperformance suggests resilience amid broader market volatility. Yet, the stock’s day performance today was flat, down just 0.01%, while the Sensex fell 0.67%, indicating a relative stability in the face of short-term market pressures. Is this short-term stability a sign of consolidation or a pause before further moves?

Moving Average Configuration: Technical Strength Across All Horizons

The technical picture for Sun Pharmaceutical Industries Ltd is robust, with the stock trading above all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This alignment indicates a strong upward trend across short, medium, and long-term horizons. Being above the 200-day moving average is particularly significant, as it often signals a sustained bullish trend rather than a temporary rally. The stock is also just 1.72% away from its 52-week high of Rs 1917.15, underscoring the strength of its recent price action. This technical strength complements the fundamental valuation premium and the positive performance metrics. Is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Context: Pharmaceuticals & Biotechnology Showing Broad Strength

The Pharmaceuticals & Biotechnology sector has delivered predominantly positive results recently, with 15 stocks having declared results so far. Of these, 12 reported positive outcomes, 2 were flat, and only 1 was negative. This sector-wide strength provides a supportive backdrop for Sun Pharmaceutical Industries Ltd, which is one of the largest constituents by market capitalisation at Rs 4,51,530.85 crores. The sector’s overall positive earnings momentum aligns with the stock’s premium valuation and strong price performance. However, the sector’s breadth of positive results also raises the question of relative valuation — does the premium P/E adequately reflect the company’s competitive positioning within this strong sector?

Rating Context: Previously Strong Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Strong Buy by MarketsMOJO, with a Mojo Score of 78.0. The rating was updated on 18 May 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. While the current rating is not disclosed, the data-driven approach behind the reassessment considers the stock’s valuation premium, consistent outperformance versus the Sensex, and strong technical positioning. This comprehensive analysis helps investors understand the nuanced balance between valuation and performance. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: Data Reflects a Balanced Yet Positive Outlook

The data for Sun Pharmaceutical Industries Ltd reveals a stock trading at a modest premium to its sector, supported by consistent outperformance across multiple timeframes and a strong technical setup. The stock’s position above all major moving averages and proximity to its 52-week high underscore a sustained upward trend. Meanwhile, the Pharmaceuticals & Biotechnology sector’s broadly positive results provide a favourable environment. The reassessment of the rating from Strong Buy reflects a careful weighing of these factors, balancing valuation against performance and technical signals. What does the current rating mean for investors looking at this large-cap stock today?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →